Oncode Scientific

Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Menu
Asset 17mdpi


ONCODEcipher Liquid28

Non-invasive NGS panel targeting 28 genes mutation using liquid biopsy (blood) to provide treatment options & prognostic indications
Learn More
Asset 12mdpi


ONCODEcipher Lung Absolute 2.0

NGS panel targeting 14 genes commonly altered in lung cancer including fusions (ALK, ROS1, MET, RET, NTRK etc.) and mutations (EGFR, KRAS, BRAF, ALK, ERBB2 etc.) Learn More
Asset 10mdpi


ONCODEcipher Breast & Ovarian Core28

NGS panel targeting 28 clinically relevant and actionable genes commonly mutated in ALL solid tumours including BRCA1 & 2 (somatic), ESR1, PIK3CA, TP53 and others Learn More
Asset 11mdpi

ONCODEcipher Colon Essential67 + MSI

NGS panel targeting 67 relevant genetic mutations (including mutations of RAS/RAF/MEK/MAP kinase signaling pathway) AND microsatellite instability status using tissue biopsy Learn More
Asset 16mdpi


ONCODEcipher Microsatellite Instability (MSI)

PCR & Fragment analysis-based assays detecting microsatellite instability status for the discovery of treatment options
Learn More
Breast cancer

ONCODEcipher BRCA 1&2 Germline + MLPA

NGS panel targeting germline BRCA 1 & 2 mutations (100% coverage) to identify the risk of hereditary breast, ovarian, prostate, pancreatic cancers; and to seek for treatment options Learn More
Asset 15mdpi

ONCODEcipher BRAF PCR

PCR-based method to detect BRAF mutation at V600E hotpot in all solid tumours especially in melanoma


Learn More
Asset 17mdpi

ONCODEcipher Liquid28

Non-invasive NGS panel targeting 28 genes mutation using liquid biopsy (blood) to provide treatment options & prognostic indications
Learn More
Asset 12mdpi

ONCODEcipher Lung Absolute 2.0

NGS panel targeting 14 genes commonly altered in lung cancer including fusions (ALK, ROS1, MET, RET, NTRK etc.) and mutations (EGFR, KRAS, BRAF, ALK, ERBB2 etc.)
Learn More
Asset 10mdpi

ONCODEcipher Breast & Ovarian Core28

NGS panel targeting 28 clinically relevant and actionable genes commonly mutated in ALL solid tumours including BRCA1 & 2 (somatic), ESR1, PIK3CA, TP53 and others
Learn More
Asset 11mdpi

ONCODEcipher Colon Essential67 + MSI

NGS panel targeting 67 relevant genetic mutations (including mutations of RAS/RAF/MEK/MAP kinase signaling pathway) AND microsatellite instability status using tissue biopsy
Learn More
Asset 16mdpi

ONCODEcipher Microsatellite Instability (MSI)

PCR & Fragment analysis-based assays detecting microsatellite instability status for the discovery of treatment options
Learn More
Asset 14mdpi

ONCODEcipher BRCA 1&2 Germline + MLPA

NGS panel targeting germline BRCA 1 & 2 mutations (100% coverage) to identify the risk of hereditary breast, ovarian, prostate, pancreatic cancers; and to seek for treatment options
Learn More
Asset 15mdpi

ONCODEcipher BRAF PCR

PCR-based method to detect BRAF mutation at V600E hotpot in all solid tumours especially in melanoma
Learn More

ONCODEcipher Liquid28 NGS Panel

Product Description:

Non-invasive cell free circulating tumour DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the 28 genes which are known to play a role in of solid tumours using only the blood of the patients.

Highlighted Genes -- EGFR, BRAF, KRAS, ESR1, FGFR, PIK3CA, TP53, ALK resistance etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

15ml Blood in cfDNA tubes

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Lung Absolute 2.0 NGS Panel

Product Description:

FFPE TNA panel targeting both fusions and mutations in 15 genes commonly altered in lung cancer to provide treatment options & prognostic indications.

Highlighted Genes -- Fusion: ALK, ROS1, MET, NTRK, etc.; Mutation: EGFR, ERBB2, BRAF, KRAS, etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Total Nucleic Acid extracted from FFPE tissue is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial clinical bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

FFPE tissue (FFPE block or 10 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Breast & Ovarian Core28 NGS Panel

Product Description:

FFPE DNA panel targeting 28 clinically relevant and actionable genes commonly mutated in breast & ovarian cancer to provide treatment options & prognostic indications.

Highlighted Genes -- Somatic BRCA1 & BRCA2, ESR1, PIK3CA, TP53, etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

DNA extracted from FFPE tissue is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial clinical bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

FFPE tissue (FFPE block or 10 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Colon & Endometrial Essential67 + MSI Panel

Product Description:

FFPE DNA panel targeting 67 relevant genetic mutations in colon cancer AND microsatellite instability (MSI) status to provide treatment options & prognostic indications.

Highlighted Genes -- Mutations of RAS/ RAF/ MEK/ MAP kinase signalling pathway

Technique:

Next Generation Sequencing (NGS) AND
Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

Essential 67 NGS Panel
DNA extracted from FFPE tissue is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial clinical bioinformatics pipelines and annotation is done using proprietary and public databases.

MSI PCR & Fragment Analysis Panel
DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 10-15 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Microsatellite Instability (MSI) PCR Panel

Product Description:

PCR and fragment analysis-based assay targeting MSI to detect the increase in length of the microsatellite segment by comparing microsatellite allele size variations between normal and tumour samples in five mononucleotide repeat markers for the discovery of treatment options such as immunotherapy.

Target Markers -- NR-21, NR-24, BAT-26, BAT-25, & MONO-27

Technique:

Polymerase Chain Reaction (PCR) & Fragment Analysis

Test Methodology:

DNA extracted from FFPE tissue (tumour) & blood (non-tumour) is subjected to PCR & amplicons are separated and identified by fragment analysis. The pattern of amplicons for the 5 mononucleotide markers is compared between tumour and non-tumour.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide
AND 3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher BRCA1/2 Germline NGS & MLPA Panel

Product Description:

NGS and MLPA panel targeting 31 germline genes mutations with 100% coverage including SNV, small InDels, large deletions & duplications, and large genomic rearrangement (LGR) to identify the risk of hereditary cancers; and to seek for treatment options.

Highlighted Genes -- Somatic BRCA1 & BRCA2, MLH1, MSH2, MSH6, TP53, etc.

Technique:

Next Generation Sequencing (NGS) & Multiplex Ligation-Dependent Probe Amplification (MLPA)

Test Methodology:

NGS: DNA extracted from blood is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using proprietary bioinformatics pipelines.

MLPA: DNA extracted from blood is subjected to Multiplex Ligation-Dependent Probe Amplification. Fluorescent labelled amplicons are separated and quantified by capillary electrophoresis.

Specimen Requirements:

3ml Blood in EDTA tube(s)

TAT

Turn Around Time:

12-15 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher BRAF PCR Panel

Product Description:

PCR method to detect BRAF mutation at V600E hotspot in all solid tumours especially in melanoma to provide treatment options.

Gene Covered -- BRAF V600E

Technique:

Polymerase Chain Reaction (PCR)

Test Methodology:

DNA extracted from FFPE tissue is subjected to PCR with primers targeting the hotspot region & amplicons are separated and identified by agarose gel electrophoresis.

Specimen Requirements:

FFPE tissue (FFPE block or 5 unstained slides [10µm thickness] with minimal surface area of 5mm2 and at least 30% tumour cellularity) & 1 H&E stained slide

TAT

Turn Around Time:

10 working days

shipment_requirement

Shipment Requirement:

Keep specimen at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us